Technology
Health
Medical

OncoCyte

$3.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.17 (-4.61%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell OncoCyte and other stocks, options, ETFs, and crypto commission-free!

About

OncoCyte Corporation, also called OncoCyte, is a pharmaceutical company. It is focused on the discovery, development and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. Read More The company was founded in September 2009 and is headquartered in Alameda, CA.

Employees
16
Headquarters
Alameda, California
Founded
2009
Market Cap
150.05M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
373.47K
High Today
$3.80
Low Today
$3.46
Open Price
$3.73
Volume
113.30K
52 Week High
$6.92
52 Week Low
$1.17

Collections

Technology
Health
Medical
Pharmaceutical
Cancer Prevention
2015 IPO
US
North America

News

Markets Insider6h

OncoCyte to Report Fourth Quarter and Full-Year 2018 Financial Results on Monday, April 1, 2019

ALAMEDA, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the fourth quarter and year ended December 31, 2018, on Monday, April 1, 2019, after the close of the U.S. financial markets. The Company will host a conference call on Monday, April 1, 2019, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corp...

22

Earnings

-$0.22
-$0.17
-$0.12
-$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 27, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.